A combined urinary biomarker panel—including stress markers (GDF15, CYCS, and PRDX2), immune effectors (MPO and C4A), ECM proteins (COL1A1 and CCN2), and selected amino acids—could support diagnosis, patient stratification, and longitudinal monitoring in mitochondrial disease. Here, PRDX2 is linked to inborn mitochondrial metabolism disorder.